VIVIO Health, Inc.

Traditional PBMs are built on spread pricing, rebates, and opaque contracts that reward higher utilization and cost — leaving employers paying more each year while members navigate confusing formularies and inconsistent support. VIVIO's Total Drug Management program replaces the PBM entirely with a model that aligns clinical care and cost.

For the less than 5% of members driving the majority of pharmacy spend — specialty, HIV, and GLP-1 therapies — VIVIO's independent clinical review ensures the right drug, for the right person, at the right price. This means evidence-based alternatives when clinically appropriate, outcomes tracked over time, and sourcing across multiple billing channels (white bag, clear bag, buy-and-bill) anchored to Medicare ASP to secure the lowest net cost.

For the other 95% of members filling routine, non-specialty medications, the experience stays seamless: open pharmacy access (retail, mail, or thousands of independent pharmacies), automatic generic substitution, and lowest-price-at-point-of-sale — all without added steps or disruption.

The result: employers have cut total pharmacy costs by up to 50%, with 100% of specialty program fees at risk — VIVIO earns nothing except its performance-based fees.